RT Journal Article
SR Electronic
T1 Evidence that intergenerational income mobility is the strongest predictor of drug overdose deaths in U. S. Heartland counties
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.07.18.23292832
DO 10.1101/2023.07.18.23292832
A1 Heyman, Gene M.
A1 Ryu, Ehri
A1 Brownell, Hiram
YR 2023
UL http://medrxiv.org/content/early/2023/07/23/2023.07.18.23292832.abstract
AB In 2017, the Acting U. S. Secretary of Health and Human Services declared the “opioid crisis” a nation-wide health emergency. However, the crisis’s geography was not nation-wide. Many counties and towns had no overdose deaths, whereas others were home to hundreds. According to many influential research reports and news stories, geographic variation in overdose deaths was due to geographic variation in opioid prescription rates and/or geographic variation in socioeconomic factors, such as unemployment. Our goal was to test the degree to which prescription rates and socioeconomic correlates of income inequality predicted overdose deaths in the 1055 U.S. Midwest (“Heartland”) counties over the years 2006 to 2020. We used multilevel regression models to gauge the predictive strength of overdose rates and six socioeconomic measures that are correlated with income inequality. There were significant state-level and county-level differences. Intergenerational income mobility was the strongest predictor of overdose deaths, with regression coefficients that averaged about twice as large as the coefficients for opioid prescription rates. Every year, counties with greater upward intergenerational income mobility had lower overdose death rates. Social capital had the second largest regression coefficients, albeit by a small margin. Counties are the smallest demographic unit for which drug overdose rates are available; the results of this study link growing income inequality and drug overdose deaths at the county level.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data were obtained from widely used, publicly available websites, primarily the CDC and Harvard University (Opportunity Insights). The sources, with their links, are listed in the body of the paper and in reference list.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes1. cdc.gov [Internet]. Atlanta (GA): CDC Wonder: Multiple Cause of Death, 19992020 Request; [cited 2023 June 27]. Available from: https://wonder.cdc.gov/mcdicd10.html2. usdoj.gov [Internet]. Arlington (VA): United States Department of Justice Drug Enforcement Administration; [cited 2023 June 27]. Available from: https://www.deadiversion.usdoj.gov/arcos/retaildrugsummary18. stacks.cdc.gov [Internet]. Atlanta (GA): National Center for Health Statistics; [cited 2023 Jun 28]. Available from: http://doi.org/10.15620/cdc:11234027. Rossen LM, Bastian B, Warner M, Khan D, Chong Y. County-level drug overdose mortality: United States, 20032020 [Data file and Map]. National Center for Health Statistics: Hyattsville(MD); 2022. [cited 2023 Jun 28]. Available from: https://www.cdc.gov/nchs/datavisualization/drugpoisoningmortality/#datatables28. CDC Injury Center [Internet]. US: The Center; 2006-2020 [cited 2023 Jun 28]. Opioid Dispensing Rate Maps; [about 5 screens]. Available from: https://www.cdc.gov/drugoverdose/rxratemaps/index.html30. opportunityinsights.org [Internet]. Cambridge: Harvard University; c2023 [cited 2023 Jun 28]. Available from: https://opportunityinsights.orghttps://wonder.cdc.gov/mcd-icd10.htmlhttps://www.deadiversion.usdoj.gov/arcos/retail_drug_summaryhttp://doi.org/10.15620/cdc:112340https://www.cdc.gov/nchs/data-visualization/drug-poisoning-mortality/#data-tableshttps://www.cdc.gov/drugoverdose/rxrate-maps/index.htmlhttps://opportunityinsights.org